DSGN
Design Therapeutics, Inc.
Key Financials
Revenue
$0
NaN%
Net Income
$-69792000
↓ 40.7%
Operating Income
$-79467000
↓ 27.4%
EPS (Diluted)
$-1.22
↓ 38.6%
Total Assets
$226.2M
↓ 10.3%
Cash & Equivalents
$16.9M
↓ 25.3%
Total Liabilities
$13.7M
↑ 37.1%
Shareholders' Equity
$212.5M
↓ 12.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/3/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 4 | 6/11/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| SCHEDULE 13G | 6/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DSGN |
| Company Name | Design Therapeutics, Inc. |
| CIK | 1807120 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-293-4900 |